Replies to post #12690 on GTC Biotherapeutics (fka GTCB)

[gym gravity]

I hope they think about "pump head" when they design the CABG trial. They could find ATryn could help with something else, other than giving a buffer to heparin resistance. It has antinflamitroy properties and that could be a factor in recovery or something else.

I have to read up on atherosclerosis.

[DewDiligence]

CABG/HR is a $100-200M market in the US — very much smaller than the potential market for ATryn in DIC/sepsis.

The reason Ovation prefers CABG/HR for the first acquired-deficiency indication is that they think they can proceed directly to phase-3 based on GTC’s prior CABG/HR studies.